Neonatal Tetanus

Neonatal tetanus, classified under ICD-10 code A33 and ICD-11 code 1C13, is a form of tetanus affecting newborns within the first 28 days of life. It is caused by the bacterium Clostridium tetani, which produces a neurotoxin leading to characteristic muscle spasms and rigidity. The disease represents a distinct clinical entity within the broader tetanus spectrum, specific to the neonatal period and linked to exposure during the perinatal process.

The clinical presentation of neonatal tetanus follows the general tetanus syndrome, beginning with muscle rigidity that typically initiates in the jaw and neck before progressing to involve the trunk and limbs. Muscle spasms occur in episodes lasting several minutes each, recurring frequently over a period of three to four weeks. Severe spasms may produce complications including bone fractures due to forceful muscle contractions. Associated systemic manifestations may include fever, excessive sweating, headache, difficulty swallowing, hypertension, and tachycardia. The incubation period ranges from three to twenty-one days following infection, with recovery potentially requiring several months and a case fatality rate approaching ten percent in reported cases.

Source-backed detail regarding the current geographic distribution, outbreak patterns, and surveillance burden of neonatal tetanus is not yet available from the provided sources. However, neonatal tetanus historically has been associated with settings where maternal tetanus vaccination coverage is inadequate and where unhygienic delivery practices persist. The disease burden has declined substantially globally due to intensified immunization programs, though elimination efforts continue in priority regions.

Neonatal tetanus infection occurs when Clostridium tetani spores enter the newborn through the umbilical stump, typically following application of contaminated substances or use of non-sterile instruments during cord cutting or care. The spores germinate in anaerobic conditions at the wound site, producing tetanospasmin toxin that ascends peripheral nerves to the central nervous system. The primary exposure pathway is therefore environmental contamination of the umbilical cord during the immediate postnatal period.

Newborns born to mothers who have not received adequate tetanus immunization during pregnancy constitute the primary risk group for neonatal tetanus. Infants delivered under unhygienic conditions or whose umbilical cords are managed with contaminated substances face elevated exposure risk. The disease disproportionately affects populations with limited access to skilled birth attendants and maternal health services.

Prevention of neonatal tetanus relies primarily on maternal immunization with tetanus toxoid during pregnancy, which confers protective antibodies that cross the placenta to protect the newborn during the vulnerable early weeks of life. Additional preventive measures include ensuring clean delivery conditions, using sterile instruments for umbilical cord cutting, and applying antiseptic protocols for cord care. The World Health Organization's strategy for maternal and neonatal tetanus elimination emphasizes comprehensive vaccination coverage combined with improved obstetric and newborn care practices.

Neonatal tetanus surveillance requires systematic identification of cases presenting with characteristic muscle rigidity and spasms in infants under 28 days of age, with particular attention to birth history and cord care practices. The disease is a designated target for elimination under global immunization initiatives, necessitating accurate case reporting and investigation of maternal vaccination status. Surveillance systems should capture both confirmed cases and probable cases based on clinical presentation in settings where laboratory confirmation is unavailable.

1. 1 Wikidata. tetanus neonatorum.
2. 2 Wikipedia. Tetanus.

ICD-10

A33

ICD-11

1C13

Total cases

5K

Total deaths

311

Peak month

2010-09

Coverage

1 reporting countries · 2010-01-01 → 2026-04-01